The Ultimate Collection: Thyroid Disease And Glp-1 Receptor Agonist Use Captured on Camera
Use of GLP
In conclusion, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter. However, due to the low incidence of these diseases , these findings need to be examined further. Systematic Review Registration:
Thyroid Disease And Glp-1 Receptor Agonist Use
As we can see from the illustration, Thyroid Disease And Glp-1 Receptor Agonist Use has many fascinating aspects to explore.
Approach to the Patient With Thyroid Nodules
Thyroid Disease And Glp-1 Receptor Agonist Use
Abstract Glucagon-like peptide 1 receptor agonists (GLP1RAs) have rapidly changed the landscape of diabetes and obesity treatment. Enthusiasm for their use is tempered with concerns regarding their risk for inducing C-cell tumors based on preclinical studies in rodents.
Glucagon-like peptide-1 receptor ( GLP -1R) agonists are well-known for their benefits in managing obesity and diabetes. However, some studies indicate that they may elevate the risk of thyroid cancer. This study employed summary data-based Mendelian randomization (SMR) analysis, incorporating genetic data from GTEx V.8 and the UK Biobank, to assess how increased GLP -1R gene expression in ...
![Picture of glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c "glp-1_analogs [TUSOM | Pharmwiki]")
